JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on February 4, 2004; DOI: 10.1124/jpet.103.064360


0022-3565/04/3093-1108-1115$20.00
JPET 309:1108-1115, 2004
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.103.064360v1
309/3/1108    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Drafts, B. C.
Right arrow Articles by Fisher, J. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Drafts, B. C.
Right arrow Articles by Fisher, J. L.

NEUROPHARMACOLOGY

Structural Determinants of the Pharmacological Properties of the GABAA Receptor {alpha}6 Subunit

Brandon C. Drafts, and Janet L. Fisher

Department of Pharmacology, Physiology, and Neuroscience, University of South Carolina School of Medicine, Columbia, South Carolina

GABAA receptors are responsible for fast inhibitory neurotransmission in the mammalian brain and are the targets for many clinical drugs that act as antiepileptics, anxiolytics, and sedatives. The pharmacological characteristics of the receptor are largely determined by its subunit composition. Compared with all other {alpha} subtypes, the {alpha}6 subtype confers unique pharmacological properties. In particular, {alpha}6-containing receptors are more sensitive to both the agonist GABA and the antagonist amiloride. Results from chimeric constructs of the {alpha}1 and {alpha}6 subunits suggested that structural differences within the extracellular N-terminal domain were responsible for both these characteristics. Within this domain, we examined 15 amino acid residues unique to the {alpha}6 subtype. Each of these sites was individually mutated in the {alpha}6 subunit to the corresponding residue of the {alpha}1 subunit. The mutated subunits were expressed in human embryonic kidney-293T cells along with wild-type {beta}3 and {gamma}2L subunits and sensitivity to GABA and amiloride determined with whole-cell electrophysiological recordings. Serine83 in the {alpha}6 subunit influenced sensitivity to both GABA and amiloride. Leucine174 and tyrosine175 were also found to contribute to inhibition by amiloride but did not affect GABA sensitivity. These structural differences are at least partly responsible for the unique pharmacological properties associated with the {alpha}6 subunit.


Received for publication December 13, 2003
Accepted February 3, 2004.

Address correspondence to: Dr. Janet L. Fisher, Department of Pharmacology, Physiology, and Neuroscience, University of South Carolina School of Medicine, Columbia, SC 29208. E-mail: jfisher{at}med.sc.edu




This article has been cited by other articles:


Home page
J. Pharmacol. Exp. Ther.Home page
B. C. Drafts and J. L. Fisher
Identification of Structures within GABAA Receptor {alpha} Subunits That Regulate the Agonist Action of Pentobarbital
J. Pharmacol. Exp. Ther., September 1, 2006; 318(3): 1094 - 1101.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics.